$20.75 0.00 (0%)
2/10/2012 4:00 PM

The Medicines Company (NASDAQ:MDCO)

CAPS Rating: 4 out of 5

A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.

Results 1 - 15 of 15

Recs

0
Member Avatar HardnoseDotCom (73.70) Submitted: 4/25/2011 1:35:10 PM : Outperform Start Price: $16.17 MDCO Score: +27.77

low PEG, strong price uptrend

Recs

0
Member Avatar medsmall (< 20) Submitted: 4/5/2011 9:32:19 AM : Outperform Start Price: $16.31 MDCO Score: +26.24

Price/earnings of 8.28, market cap of 866.36, debt/equity of zero, Return on Invested Capital (TTM) of 35.00, based in New Jersey, United States, pharma company with focus on critical care patients.

Recs

0
Member Avatar HP2006 (92.12) Submitted: 4/1/2011 7:50:16 PM : Outperform Start Price: $16.40 MDCO Score: +25.83

screen

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 3/23/2011 8:32:07 AM : Outperform Start Price: $16.11 MDCO Score: +24.59

Yahoo small cap value and growth

Recs

0
Member Avatar ruinas (< 20) Submitted: 10/11/2010 11:16:44 AM : Outperform Start Price: $13.55 MDCO Score: +37.95

Improving profits in current environment plus recent FDA approval of new product.

Recs

0
Member Avatar Magnet0 (89.30) Submitted: 5/13/2009 5:50:39 PM : Outperform Start Price: $7.22 MDCO Score: +134.38

quality company, took a fatty nose dive

Recs

1
Member Avatar zzlangerhans (99.26) Submitted: 2/20/2009 1:07:40 PM : Outperform Start Price: $12.61 MDCO Score: -15.16

It's not clear to me why Medicines has fallen so far despite a relatively stable financial picture. Angiomax revenues have been increasing and generics will not be available before 2010 at the earliest. That gives Medicines time to grow Cleviprex revenues and develop their pipeline. I'm not really a bull here but this company has the tools to survive and will likely be one to rebound in the short term when the market stabilizes, given no major negative catalysts.

Recs

0
Member Avatar escarzamd (70.03) Submitted: 5/31/2008 2:26:29 PM : Outperform Start Price: $18.25 MDCO Score: +14.05

Hearing good things from cardiologists about Angiomax. recent support from journals. Could be a combo w/BMY for cath patients. No debt on board, so if this drug hits.......the stock could go out of the yard.

Recs

1
Member Avatar popsstocs (< 20) Submitted: 9/8/2007 3:39:10 PM : Outperform Start Price: $16.47 MDCO Score: +29.46

I have made some good profits off this CO.I guess it makes all that money from selling all those expensive medications,but what ever,It does me good and I played it again,and its already on its way to do ole pops right again.

Recs

0
Member Avatar StocksdatROCK (40.35) Submitted: 9/4/2007 7:53:25 PM : Outperform Start Price: $16.81 MDCO Score: +28.00

Has the worlds favorite item and to many customers

Recs

0
Member Avatar almond9090 (37.61) Submitted: 8/17/2007 5:43:16 AM : Outperform Start Price: $16.50 MDCO Score: +28.55

Consistent steady growth with well-established product should slightly outperform the market.

Recs

0
Member Avatar aaroger (< 20) Submitted: 7/27/2007 10:45:14 AM : Outperform Start Price: $17.21 MDCO Score: +25.10

34

Recs

1
Member Avatar agard43 (30.60) Submitted: 3/22/2007 10:31:33 PM : Underperform Start Price: $25.17 MDCO Score: +16.70

TheStreet.com: "There still seems to be a lot of hope built into the stock price. As Morgan Stanley analyst Stephen Herr wrote this week, "if the patent life is not extended, this stock looks broadly overvalued."

Recs

0
Member Avatar naygoo (52.27) Submitted: 12/11/2006 1:50:32 PM : Underperform Start Price: $30.96 MDCO Score: +33.52

Shares of the Medicines Co. (NASDAQ:MDCO - News) fell 10 percent on Monday after the U.S. Congress failed to enact a bill that would have helped the company's bid to extend a patent on its flagship drug Angiomax, a blood thinner.

Recs

0
Member Avatar walchak (< 20) Submitted: 8/26/2006 3:16:19 PM : Outperform Start Price: $22.00 MDCO Score: -16.15

their primary anticoagulant medicine is being used increasingly in the cardiology community for increased safety considerations and their next medicine in the pipeline may be even bigger

Results 1 - 15 of 15

Featured Broker Partners


Advertisement